You are here: Industry Insights > obesity

News List

Saxenda® recommended for approval by European Medicines Agency committee for the treatment of obesity in adolescents aged 12-17 years prnasia
March 29, 2021
Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use of Saxenda® is expanded for the treatment of obesity in adolescents aged 12–17 years.
Adults with obesity treated with semaglutide 2.4 mg achieved and maintained a significant amount of weight loss in a 68-week trial prnasia
March 24, 2021
New results from the STEP phase 3a clinical trial programme demonstrated weight loss with investigational treatment of once-weekly subcutaneous semaglutide 2.4 mg versus placebo.
Boehringer Ingelheim, Gubra to validate new Peptides for obesity pharmaceutical-business-review
March 05, 2021
Boehringer Ingelheim has entered into a new research and licensing agreement with biotech company Gubra to identify and validate innovative peptides to treat obesity.
Sciwind's Investigational New Drug Approved for NASH Trial prnasia
March 01, 2021
Hangzhou Sciwind Biosciences Co., Ltd. today announced that XW003, a potential candidate for the treatment of non-alcoholic steatohepatitis (NASH), has been approved by China NMPA for clinical trial.
Novo Nordisk’s semaglutide cuts body weight in large-scale trial pharmatimes
February 24, 2021
Novo Nordisk’s glucagon-like peptide-1 (GLP-1) agonist semaglutide significantly cut body weight in a large-scale trial of adults who are overweight or obese.
February Pharmacovigilance Risk Assessment Committee (PRAC) meeting highlights europeanpharmaceuticalreview
February 19, 2021
The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) began two new reviews and wrote guidance for healthcare professionals on the potential side effects of Strimvelis, Venclyxto and Zolgensma.
UK researchers find semaglutide could be a ‘game changer’ drug to fight obesity expresspharma
February 18, 2021
The drug, semaglutide, works by hijacking the body's own appetite-regulating system in the brain leading to reduced hunger and calorie intake, according to the study.
Semaglutide 2.4 mg injection demonstrated significant weight loss versus placebo when added to intensive behavioural therapy prnasia
November 06, 2020
Results of a phase 3a trial showed that investigational drug semaglutide 2.4 mg once-weekly subcutaneous as an adjunct to intensive behavioural therapy (IBT) demonstrated significantly more body weight loss compared to placebo plus IBT.
NICE recommends Liraglutide for treatment of obesity and non-diabetic hyperglycaemia europeanpharmaceuticalreview
November 06, 2020
Liraglutide (Saxenda) will be offered to adults with non-diabetic hyperglycaemia and a high risk of cardiovascular disease.
NICE recommends Novo Nordisk treatment for adults with obesity pharmaceutical-technology
November 02, 2020
National Institute for Health and Care Excellence (NICE) has recommended a new treatment option developed by Novo Nordisk for adults with obesity and non-diabetic hyperglycaemia.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page